Results 11 to 20 of about 569,111 (191)

Acute Myeloid Leukemia [PDF]

Methods in Molecular Biology, 2017
Acute myeloid leukemia (AML) is the most common type of leukemia. The Cancer Genome Atlas Research Network has demonstrated the increasing genomic complexity of acute myeloid leukemia (AML).
Fortina, P, Kricka, Lj, Londin, E, Park, Jy   +3 more
core   +2 more sources

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

New England Journal of Medicine, 2016
BACKGROUND The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear.
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +3 more sources

International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data.

Blood, 2022
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology.
D. Arber, A. Orazi, R. Hasserjian, M. Borowitz, K. Calvo, H. Kvasnicka, Sa A. Wang, A. Bagg, T. Barbui, S. Branford, C. Bueso-Ramos, J. Cortes, P. Dal Cin, C. Dinardo, H. Dombret, E. Duncavage, B. Ebert, E. Estey, F. Facchetti, K. Foucar, N. Gangat, U. Gianelli, L. Godley, N. Goekbuget, J. Gotlib, E. Hellström-Lindberg, G. Hobbs, R. Hoffman, E. Jabbour, J. Kiladjian, R. Larson, M. L. Le Beau, M. Loh, B. Löwenberg, E. Macintyre, L. Malcovati, C. Mullighan, C. Niemeyer, O. Odenike, S. Ogawa, A. Órfão, E. Papaemmanuil, F. Passamonti, K. Porkka, C. Pui, J. Radich, A. Reiter, M. Rozman, M. Rudelius, M. Savona, C. Schiffer, Annette Schmitt-Graeff, A. Shimamura, J. Sierra, W. Stock, R. Stone, M. Tallman, J. Thiele, H. Tien, A. Tzankov, A. Vannucchi, P. Vyas, A. Wei, O. Weinberg, A. Wierzbowska, M. Cazzola, H. Döhner, A. Tefferi   +67 more
semanticscholar   +1 more source

Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell cancer characterized by unbridled proliferation of malignant marrow stem cells with associated infection, anemia, and bleeding.
S. Shimony, Maximilian F. Stahl, R. Stone   +2 more
semanticscholar   +1 more source

Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2023
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues.
D. Pollyea, J. Altman, R. Assi, D. Bixby, A. Fathi, J. Foran, I. Gojo, Aric Hall, B. Jonas, A. Kishtagari, J. Lancet, L. Maness, J. Mangan, G. Mannis, G. Marcucci, A. Mims, Kelsey Moriarty, Moaath K. Mustafa Ali, Jadee L. Neff, R. Nejati, R. Olin, M. Percival, A. Perl, Amanda C. Przespolewski, D. Rao, F. Ravandi, R. Shallis, P. Shami, E. Stein, R. Stone, K. Sweet, Swapna Thota, G. Uy, P. Vachhani, Carly J Cassara, Deborah A. Freedman-Cass, Katie Stehman   +36 more
semanticscholar   +1 more source

Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.

New England Journal of Medicine, 2022
BACKGROUND The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia ...
P. Montesinos, C. Récher, S. Vives, E. Zarzycka, Jianxiang Wang, Giambattista Bertani, M. Heuser, R. Calado, A. Schuh, S. Yeh, S. Daigle, J. Hui, S. Pandya, D. Gianolio, S. de Botton, H. Döhner   +15 more
semanticscholar   +1 more source

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

New England Journal of Medicine, 2020
BACKGROUND Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
C. Dinardo, B. Jonas, V. Pullarkat, M. Thirman, Jacqueline S. Garcia, A. Wei, M. Konopleva, H. Döhner, A. Letai, P. Fenaux, E. Koller, V. Havelange, B. Leber, J. Esteve, Jianxiang Wang, V. Pejsa, R. Hájek, K. Porkka, Á. Illés, D. Lavie, R. Lemoli, Kazuhito Yamamoto, S. Yoon, J. Jang, S. Yeh, M. Turgut, W. Hong, Ying Zhou, J. Potluri, K. Pratz   +29 more
semanticscholar   +1 more source

Acute myeloid leukemia: current progress and future directions

Blood Cancer Journal, 2021
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
H. Kantarjian, T. Kadia, C. Dinardo, N. Daver, G. Borthakur, E. Jabbour, G. Garcia-Manero, M. Konopleva, F. Ravandi   +8 more
semanticscholar   +1 more source

Advances in acute myeloid leukemia

British medical journal, 2021
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis ...
L. Newell, R. Cook
semanticscholar   +1 more source

Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). [PDF]

, 2011
We report an allelic series of eight mutations in GATA2 underlying Emberger syndrome, an autosomal dominant primary lymphedema associated with a predisposition to acute myeloid leukemia.
C Preudhomme, Colin G Steward, Daniela T Pilz, Dimitra Dafou, F-Y Tsai, Fiona C Connell, Glen Brice, Ines Martinez-Corral, M Haugas, M Khandekar, Michael A Simpson, ML Smith, NP Rodrigues, P Callier, Peter Lunt, Peter S Mortimer, Pia Ostergaard, Q Tong, R Zheng, Richard C Trembath, Russell Keenan, S Mansour, S-J Zhang, Sahar Mansour, Sarah Smithson, Shirley Hodgson, Steve Jeffery, T Pabst, Taija Makinen, Tatjana Kilo, Victoria A Murday, W-J Song, Wesley J Woollard   +32 more
core   +1 more source